Resistance is futile: The bacteriocin model for addressing the antibiotic resistance challenge

Biochemical Society Transactions

Volumn 40, Issue 6, 2012, Pages 1438-1442

  Riley, Margaret A ^a   Robinson, Sandra M ^a   Roy, Christopher M ^a   Dennis, Morgan ^a   Liu, Vivian ^a   Dorit, Robert L ^b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b SMITH COLLEGE   (United States)

Author keywords

Antibiotic; Bacteriocin; Targeted therapeutic; Urinary tract infection (UTI)

Indexed keywords

AMOXICILLIN; AMPICILLIN; BACTERIOCIN;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; ENTEROCOCCUS FAECIUM; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; MICROBIAL COMMUNITY; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIURIA; COLICINS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84870228652     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20120179     Document Type: Conference Paper

References (44)

1. Bush, K., Courvalin, P., Dantas, G., Davies, J., Eisenstein, B., Huovinen, P., Jacoby, G.A., Kishony, R., Kreiswirth, B.N., Kutter, E. et al. (2011) Tackling antibiotic resistance. Nat. Rev. Microbiol. 9, 894-896
2. Levy, S.B. and Marshall, B. (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10, S122-S129 (Pubitemid 40018235)
3. Livermore, D.M. (2003) Bacterial resistance: origins, epidemiology, and impact. Clin. Infect. Dis. 36, S11-S23
4. Pitout, J.D.D. and Laupland, K.B. (2008) Extended-spectrum β-lactamase-producing enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8, 159-166
5. Arias, C.A. and Murray, B.E. (2009) Antibiotic-resistant bugs in the 21st century: a clinical super-challenge. N. Engl. J. Med. 360, 439-443
6. Fischbach, M.A. and Walsh, C.T. (2009) Antibiotics for emerging pathogens. Science 325, 1089-1093
7. Reference deleted
8. Roberts, R.R., Hota, B., Ahmad, I., Scott, R.D., Foster, S.D., Abbasi, F., Schabowski, S., Kampe, L.M., Ciavarella, G.G., Supino, M. et al. (2009) Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis. 49, 1175-1184
9. Mainous, III, A.G. and Pomeroy, C. (eds) (2010) Management of Antimicrobials in Infectious Diseases: Impact of Antibiotic Resistance, Humana Press, Totowa
10. Nugent, R., Back, E. and Beith, A. (2010) The Race Against Drug Resistance: a Report of the Center for Global Development's Drug Resistance Working Group, Center For Global Development, Washington, DC
11. Food and Drug Administration (2010) The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals, Food and Drug Administration, Rockville
12. Andremont, A., Bonten, M., Kluytmans, J., Carmeli, Y., Cars, O. and Harbarth, S. (2011) Fighting bacterial resistance at the root: need for adapted EMEA guidelines. Lancet Infect. Dis. 11, 6-8
13. Goff, D.A. (2011) Antimicrobial stewardship: bridging the gap between quality care and cost. Curr. Opin. Infect. Dis. 24 (Suppl. 1), S11-S20
14. Riley, M.A., Goldstone, C.M., Wertz, J.E. and Gordon, D. (2003) A phylogenetic approach to assessing the targets of microbial warfare. J. Evol. Biol. 16, 690-697 (Pubitemid 36832267)
15. Riley, M.A. and Wertz, J.E. (2002) Bacteriocins: evolution, ecology, and application. Annu. Rev. Microbiol. 56, 117-137 (Pubitemid 35217450)
16. Barbosa, T.M. and Levy, S.B. (2000) The impact of antibiotic use on resistance development and persistence. Drug Resist. Updates 3, 303-311
17. Zucca, M. and Savoia, D. (2010) The post-antibiotic era: promising developments in the therapy of infectious diseases. Int. J. Biomed. Sci. 6, 77-86
18. Yilmaz, N., Agus, N., Yurtsever, S.G., Pullukcu, H., Gulay, Z., Coskuner, A., Kose, S., Aydemir, S., Gulenc, N. and Ozgenc, O. (2009) Prevalence and antimicrobial susceptibility of Escherichia coli in outpatient urinary isolates in Izmir, Turkey. Med. Sci. Monit. 15, PI61-PI65
19. Harding, G.K. and Ronald, A.R. (1994) The management of urinary infections: what have we learned in the past decade? Int. J. Antimicrob. Agents 4, 83-88 (Pubitemid 24187398)
20. Stamm, W.E. and Norrby, S.R. (2001) Urinary tract infections: disease panorama and challenges. J. Infect. Dis. 183 (Suppl. 1), S1-S4 (Pubitemid 32174135)
21. Brumfitt, W. and Hamilton-Miller, J.M. (1998) Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience. J. Antimicrob. Chemother. 42, 363-371 (Pubitemid 28442450)
22. Foxman, B. (1990) Recurring urinary tract infection: incidence and risk factors. Am. J. Public Health 80, 331-333
23. Hooton, T.M. (2000) Pathogenesis of urinary tract infections: an update. J. Antimicrob. Chemother. 46 (Suppl. A), 1-7
24. Hooton, T.M. and Stamm, W.E. (1997) Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. North Am. 11, 551-581 (Pubitemid 27445472)
25. Warren, J.W. (1997) Catheter-associated urinary tract infections. Infect. Dis. Clin. North Am. 11, 609-622
26. Foxman, B. (2003) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. DM, Dis.-Mon. 49, 53-70
27. Kunin, C.M. (1997) Antibiotic armageddon. Clin. Infect. Dis. 25, 240-241
28. Karlowsky, J.A., Hoban, D.J., Decorby, M.R., Laing, N.M. and Zhanel, G.G. (2006) Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob. Agents Chemother. 50, 2251-2254 (Pubitemid 43807558)
29. Hamilton-Miller, J.M. (1998) 'Think like a bacterium': a helpful concept to prolong the antibiotic era? Clin. Microbiol. Infect. 4, 177-178
30. Stickler, D.J. (2008) Bacterial biofilms in patients with indwelling urinary catheters. Nat. Clin. Pract. Urol. 5, 598-608
31. Felmingham, D. and Arakawa, S. (2001) Resistance among urinary tract pathogens: experience outside the USA. Clin. Drug Invest. 21, 7-11 (Pubitemid 32230897)
32. Gupta, K., Hooton, T.M. and Stamm, W.E. (2001) Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Int. Med. 135, 41-50 (Pubitemid 32619282)
33. Kahlmeter, G. (2003) An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J. Antimicrob. Chemother. 51, 69-76
34. Karlowsky, J.A., Kelly, L.J., Thornsberry, C., Jones, M.E. and Sahm, D.F. (2002) Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the united states. Antimicrob. Agents Chemother. 46, 2540-2545 (Pubitemid 34793461)
35. Mazzulli, T. (2002) Resistance trends in urinary tract pathogens and impact on management. J. Urol. 168, 1720-1722
36. Murray, B.E., Alvarado, T., Kim, K.H., Vorachit, M., Jayanetra, P., Levine, M.M., Prenzel, I., Fling, M., Elwell, L., McCracken, G.H. et al. (1985) Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries. J. Infect. Dis. 152, 1107-1113
37. Seifert, R., Weinstein, D.M. and Li-McLeod, J. (2001) National prevalence of Escherichia coli resistance to trimethoprim-sulfamethoxazole: managed care implications in the treatment of urinary tract infections. J. Manag. Care Pharm. 7, 132
38. Talan, D.A., Stamm, W.E., Hooton, T.M., Moran, G.J., Burke, T., Iravani, A., Reuning-Scherer, J. and Church, D.A. (2000) Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA, J. Am. Med. Assoc. 283, 1583-1590 (Pubitemid 30161514)
39. Miller, L.G. and Tang, A.W. (2004) Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin. Proc. 79, 1048-1053
40. Nickel, J.C. (2005) Management of urinary tract infections: historical perspective and current strategies. Part 1. Before antibiotics. J. Urol. 173, 21-26
41. Gupta, V., Yadav, A. and Joshi, R.M. (2002) Antibiotic resistance pattern in uropathogens. Indian J. Med. Microbiol. 20, 96-98
42. Raz, R., Chazan, B., Kennes, Y., Colodner, R., Rottensterich, E., Dan, M., Lavi, I. and Stamm, W. (2002) Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 34, 1165-1169 (Pubitemid 34450662)
43. Smith, K., Martin, L., Rinaldi, A., Rajendran, R., Ramage, G. and Walker, D. (2012) Activity of pyocin s2 against Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 56, 1599-1601
44. Trautner, B.W., Hull, R.A. and Darouiche, R.O. (2005) Prevention of catheter-associated urinary tract infection. Curr. Opin. Infect. Dis. 18, 37-41 (Pubitemid 41716238)